Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPMCNASDAQ:SRPTNASDAQ:TLXNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$128.40+0.0%$114.35$73.04▼$128.52$8.29B0.891.33 million shs1.94 million shsSRPTSarepta Therapeutics$17.32-5.0%$34.46$16.88▼$154.90$1.79B0.452.20 million shs4.14 million shsTLXTelix Pharmaceuticals$15.48-3.7%$16.81$13.61▼$30.36$5.44BN/A28,752 shs54,654 shsVERAVera Therapeutics$22.97-4.3%$22.73$18.53▼$51.61$1.53B1.19990,357 shs822,985 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines0.00%+0.12%+0.33%+59.94%+14.83%SRPTSarepta Therapeutics0.00%+6.46%-57.65%-65.24%-88.00%TLXTelix Pharmaceuticals0.00%+0.77%-3.85%+13.15%+1,612,399,900.00%VERAVera Therapeutics0.00%+4.83%+4.60%+19.08%-33.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMCBlueprint Medicines1.3655 of 5 stars2.14.00.00.01.50.80.6SRPTSarepta Therapeutics4.7225 of 5 stars4.22.00.04.22.41.71.9TLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVERAVera Therapeutics3.3199 of 5 stars4.61.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMCBlueprint Medicines 2.27Hold$128.06-0.27% DownsideSRPTSarepta Therapeutics 2.44Hold$60.88251.47% UpsideTLXTelix Pharmaceuticals 3.00Buy$22.3344.27% UpsideVERAVera Therapeutics 3.10Buy$65.00182.98% UpsideCurrent Analyst Ratings BreakdownLatest VERA, BPMC, TLX, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell6/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMCBlueprint Medicines$508.82M16.30N/AN/A$4.70 per share27.32SRPTSarepta Therapeutics$1.90B0.89$2.31 per share7.49$15.99 per share1.08TLXTelix Pharmaceuticals$516.72M10.14$0.11 per share140.73$1.12 per share13.82VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMCBlueprint Medicines-$67.09M-$2.47N/A197.54N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.58N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0032.25N/AN/AN/AN/AN/AVERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest VERA, BPMC, TLX, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMCBlueprint MedicinesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMCBlueprint Medicines1.012.802.75SRPTSarepta Therapeutics1.004.022.46TLXTelix Pharmaceuticals0.992.782.66VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMCBlueprint MedicinesN/ASRPTSarepta Therapeutics86.68%TLXTelix PharmaceuticalsN/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipBPMCBlueprint Medicines4.21%SRPTSarepta Therapeutics7.70%TLXTelix PharmaceuticalsN/AVERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableTLXTelix PharmaceuticalsN/A338.38 millionN/AN/AVERAVera Therapeutics4063.77 million53.38 millionOptionableVERA, BPMC, TLX, and SRPT HeadlinesRecent News About These CompaniesVera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA NephropathyJuly 6 at 4:38 AM | msn.comVera Therapeutics Inc Class A Sustainability - MorningstarJuly 5 at 10:09 PM | morningstar.comMVera Therapeutics (NASDAQ:VERA) Shares Gap Up on Insider Buying ActivityJune 28, 2025 | americanbankingnews.comVera Therapeutics director Enright buys shares worth $5.2mJune 27, 2025 | investing.comVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingJune 27, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying ActivityJune 26, 2025 | marketbeat.comInsider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of StockJune 26, 2025 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 SharesJune 25, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 SharesJune 25, 2025 | marketbeat.comPolycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsightJune 24, 2025 | theglobeandmail.comBAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsightJune 24, 2025 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateJune 18, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)...June 12, 2025 | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka, Vera stake their claims to IgAN treatmentJune 9, 2025 | pharmaphorum.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom5 Small Cap Stocks With Explosive Upside PotentialBy Ryan Hasson | June 23, 2025View 5 Small Cap Stocks With Explosive Upside PotentialVERA, BPMC, TLX, and SRPT Company DescriptionsBlueprint Medicines NASDAQ:BPMC$128.40 +0.05 (+0.04%) As of 04:00 PM EasternBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$17.32 -0.92 (-5.04%) Closing price 04:00 PM EasternExtended Trading$17.40 +0.08 (+0.46%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Telix Pharmaceuticals NASDAQ:TLX$15.48 -0.59 (-3.67%) As of 04:00 PM EasternTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Vera Therapeutics NASDAQ:VERA$22.97 -1.03 (-4.29%) Closing price 04:00 PM EasternExtended Trading$22.86 -0.11 (-0.46%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
